The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2023 | Improved life expectancy of patients with thalassemia and the challenges this presents
Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, highlights the progress which has been made over the past decades in the treatment of thalassemia, leading to an increased life expectancy of patients with the disease. This has resulted in a greater number of elderly patients with the disease, in which factors such as comorbidities and maintaining quality of life must be considered.
This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
